Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7bb8b95d7b-qxsvm Total loading time: 0 Render date: 2024-09-25T21:06:08.592Z Has data issue: false hasContentIssue false

III - Pathophysiology of Ovarian Hyperstimulation Syndrome

Published online by Cambridge University Press:  11 August 2009

Botros Rizk
Botros Rizk
Affiliation:
University of South Alabama
Get access

Summary

Rizk et al. (1997) have extensively reviewed the pathophysiology of OHSS. OHSS is marked by massive bilateral cystic ovarian enlargement (Figure I.1). The ovaries are noted to have a significant degree of stromal edema, interspersed with multiple hemorrhagic follicular and theca-lutein cysts, areas of cortical necrosis and neovascularization. The second pathological phenomenon is that of acute body fluid shifts, resulting in ascites (Figure I.2) and pleural effusion. Most investigators believe that these fluid shifts are the result of enhanced capillary permeability (Rizk and Aboulghar, 1991, 1999; El-Chalal and Schenker, 1997; Kaiser, 2003). This has been demonstrated in several animal models including hyperstimulated rats (Gomez et al., 2002), and rabbits (Schenker and Weinstein, 1978). More recently, Tollan et al. (1990) showed that, during ovarian stimulation for IVF, there is infiltration of fluid from the vascular space to the interstitial compartment one day before oocyte aspiration. Significant advances have been made in our understanding of the nature of the vasoactive agents involved (Figure III.1).

ROLE OF PERIPHERAL ARTERIOLAR DILATATION

In contrast to our classic concept of increased capillary permeability (Rizk, 1993a, b; Aboulghar et al., 1996; Rizk et al., 1997). Balasch et al. (1991) adopted a very different and interesting view. They studied the hemodynamic changes in severe OHSS and suggested that the circulatory disturbances are not secondary to reduction in circulating blood volume, but are a consequence of an intense peripheral arteriolar vasodilatation that leads to underfilling of the arterial vascular component, arterial hypotension and a compensatory increase in heart rate and cardiac output (Balasch et al., 1991).

Type
Chapter
Information
Ovarian Hyperstimulation Syndrome
Epidemiology, Pathophysiology, Prevention and Management
 , pp. 43 - 78
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aboulghar, MA, Mansour, RT, Serour, GI & Rizk, B (1996). Ovarian hyperstimulation syndrome: modern concepts in pathophysiology and management. Middle East Fertil Soc J 1:3–16.Google Scholar
Aboulghar, MA, Mansour, RT, Serour, GI et al. (1998). Elevated levels of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Hum Reprod 13:2068–71.CrossRefGoogle Scholar
Aboulghar, MA, Mansour, RT, Serour, GI et al. (1999). Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 87:81–5.CrossRefGoogle ScholarPubMed
Abramov, Y, Schenker, JG, Lewin, A et al. (1996). Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 11:1381–6.CrossRefGoogle ScholarPubMed
Abramov, Y, Barak, V, Nisman, B et al. (1997). Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 67:261–5.CrossRefGoogle ScholarPubMed
Abramov, Y, Naparstek, Y, Elchalal, U et al. (1999). Plasma immunoglobulins in patients with severe ovarian hyperstimulation syndromeFertil Steril 71:102–5.CrossRefGoogle ScholarPubMed
Abramov, Y, Schenker, JG, Lewin, A et al. (2001). Soluble ICAM-1 and E-selection levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Fertil Steril 76:51–7.CrossRefGoogle Scholar
Adashi, EY (1990). The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series. Endocr Rev 11:454–64.CrossRefGoogle ScholarPubMed
Agrawal, R, Conway, G, Sladkevicius, P et al. (1998). Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 79:651–8.CrossRefGoogle Scholar
Agrawal, R, Tan, SL, Wild, S et al. (1999). Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71:278–93.CrossRefGoogle ScholarPubMed
Albert, C, Garrido, N, Mercader, A et al. (2002). The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 8:409–18.CrossRefGoogle ScholarPubMed
Alonso-Muriel, I, Gomez-Gallego, R, Pau, E et al. (2005). Free VEGF but not total VEGF is responsible for ovarian hyperstimulation syndrome (OHSS) onset. J Soc Gyn Invest 12 (Suppl 6):87A.Google Scholar
Ando, H, Furugori, K, Shibata, K et al. (2003). Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome recieving IVF and elective embryo cryopreservation: a case series. Hum Reprod 18:1219–22.CrossRefGoogle Scholar
Artini, PG, Fasciani, A, Monti, M et al. (1998) Changes in vascular endothelial growth factor concentrations and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 70:560–4.CrossRefGoogle Scholar
Asch, RH, Li, HP, Balmeceda, JP et al. (1991). Severe ovarian hyperstimulation syndrome in assisted reproductive technology; definition of high risk groups. Hum Reprod 6:1395–9.CrossRefGoogle ScholarPubMed
Balasch, J, Carmona, F, Llach, J et al. (1990). Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod 5:348–51.CrossRefGoogle Scholar
Balasch, J, Arroyo, V, Carmona, F et al. (1991). Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertil Steril 56:1077–83.CrossRefGoogle ScholarPubMed
Balasch, J, Arroyo, V, Fabregues, F et al. (1994). Neurohormonal and hemodynamic changes in severe cases of ovarian hyperstimulation syndrome. Ann Intern Med 121:27–33.CrossRefGoogle ScholarPubMed
Barak, V, Mordel, N, Zakicek, G et al. (1992). The correlation between interleukin 2 and interleukin 2 receptors to oestradiol, progesterone and testosterone levels in preovulatory follicles of in vitro fertilization patients. Hum Reprod 7:926–9.CrossRefGoogle Scholar
Barak, V, Elchalal, U, Edelstein, M et al. (2004). Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 82:415–20.CrossRefGoogle ScholarPubMed
Banarjee, SK, Sarkar, DK, Weston, AP et al. (1997). Over expression of vascular endothelial growth factor and its receptors during the development of estrogen induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 18:1155–61.CrossRefGoogle Scholar
Ben-Rafael, Z & Orvieto, R (1992). Cytokines-involvement in reproduction. Fertil Steril 58:1093–9.CrossRefGoogle ScholarPubMed
Blankestijn, PF, Derkx, FHM, Geelen, JA et al. (1990). Increase in plasma prorenin during the mesntrual cycle of a bilaterally nephrectomized woman. Br J Obstet Gynaecol 97:1038–42.CrossRefGoogle Scholar
Borenstein, R, Elhalah, U, Lunenfeld, B & Schwartz, ZS (1989). Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 51:791–5.CrossRefGoogle ScholarPubMed
Buyalos, RP, Watson, JM, Martinez Maza, O et al. (1992). Detection of IL-6 in human follicular fluid. Fertil Steril 57:1230–40.CrossRefGoogle ScholarPubMed
Castelbaum, AJ, Bigdeli, H, Post, KD et al. (2002). Exacerbation of ovarian hyperstimulation by leuporlide reveals a gonadotroph adenoma. Fertil Steril 78:1311–3.CrossRefGoogle ScholarPubMed
Catargi, B, Felicie-Dellan, E & Tabarin, A (1999). Comment on gonadotrophin adenoma causing ovarian hyperstimulation. J Clin Endocrinol Metab 84:3404–6.CrossRefGoogle ScholarPubMed
Chae, HD, Park, EJ, Kim, SH et al. (2001). Ovarian hyperstimulation syndrome complicating a spontaneous singleton pregnancy: a case report. J Assist Reprod Genet 18:120–3.CrossRefGoogle ScholarPubMed
Charnock-Jones, DS, Sharkey, AM, Rajput-Williams, J et al. (1993). Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell line. Biol Reprod 48:1120–60.CrossRefGoogle Scholar
Chen, CD, Wu, MY, Chen, HF et al. (2000). Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod 15:66–71.CrossRefGoogle ScholarPubMed
Christin-Maitre, S, Rongieres-Bertrand, C, Kottler, ML et al. (1998). A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin Endocrinol Metab 83:3450–3.Google ScholarPubMed
Cohen, T, Hahari, D, Cerem-Weiss, L et al. (1996). Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–41.CrossRefGoogle ScholarPubMed
Connolly, DT, Olander, JV, Heuvelman, D et al. (1989). Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264:20017–24.Google ScholarPubMed
Culler, MD, Tarlatzis, BC, Rzasa, PJ et al. (1986). Renin-like activity in ovarian follicular fluid. J Clin Endocrinol Metab 62:613–5.CrossRefGoogle Scholar
Cunha-Filho, JS, Lemos, N, Stein, N et al. (2005). Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in vitro fertilization with a gonadotropin-releasing hormone antagonist. Fertil Steril 83:902–7.CrossRefGoogle ScholarPubMed
D'Ambrogio, G, Fasciani, A, Monti, M et al. (1999). Serum vascular endothelial growth factor levels before starting gonadotrophin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome. Gynecol Endocrinol 13:311–15.CrossRefGoogle ScholarPubMed
Damas, P, Ledoux, D, Nys, M et al. (1992). Cytokine serum level during severe sepsis in humans IL-6 as a marker of severity. Ann Surg 215:356–62.CrossRefGoogle Scholar
Daniel, Y, Geva, E, Amit, A et al. (1999). Levels of soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 are increased in women with ovarian hyperstimulation syndrome. Fertil Steril 71:896–901.CrossRefGoogle ScholarPubMed
Daniel, Y, Geva, E, Amit, A et al. (2001). Soluble endothelial and platelet selectins in serum and ascitic fluid of women with ovarian hyperstimulation syndrome. Am J Reprod Immunol 45:154–60.CrossRefGoogle ScholarPubMed
Davison, JM, Vallotton, MV & Lindheimer, MD (1981). Plasma osmolality and urinary concentration and dilution during and after pregnancy: evidence that lateral recombency inhibits maximal urinary concentrating ability. Br J Obstet Gynaecol 88:472–9.CrossRefGoogle Scholar
Davison, JM, Gilmore, EA, Durr, J et al. (1984). Altered osmotic threshold for vasopressin secretion and thirst in human pregnancy. Am J Physiol 246:F105–109.Google ScholarPubMed
Delbaere, A, Bergmann, PJM & Gervy-Decoster, C (1994). Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management. Fertil Steril 62:731–7.CrossRefGoogle ScholarPubMed
Delbaere, A, Bergmann, PJM, Gervy-Decoster, C et al. (1997). Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod 12:236–40.CrossRefGoogle ScholarPubMed
Delvigne A (2004). Epidemiology and pathophysiology of ovarian hyperstimulation syndrome. In (Gerris, G, Olivennes, F & Sutter, P, Eds), Assisted Reproductive Technologies: Quality and Safety. New York: Parthenon Publishing, Chapter 12, pp. 149–62.Google Scholar
Derkx, FHM, Stuenkel, C, Schalekamp, MPA et al. (1986). Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 63:1008–15.CrossRefGoogle ScholarPubMed
Djerassi, A, Coutifaris, C, West, VA et al. (1995). Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 80:591–4.Google Scholar
Do, YS, Sherrod, A, Lobo, RA et al. (1988). Human ovarian theca cells are a source of renin. Proc Natl Acad Sci USA 85:1957–8.CrossRefGoogle ScholarPubMed
Donnez, J, Langerock, S & Thomas, K (1982). Peritoneal fluid volume and 17β-estradiol and progesterone concentrations in ovulatory, anovulatory, and postmenopausal women. Obstet Gynecol 59:687–92.Google ScholarPubMed
El-Chalal, U & Schenker, JG (1997). The pathophysiology of ovarian hyperstimulation syndrome – views and ideas. Hum Reprod 12:1129–37.CrossRefGoogle Scholar
Enskog, A, Nilsson, L & Bränström, M (2001a). Plasma levels of free vascular endothelial growth factor165 (VEGF165) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study. Eur J Obstet Gynecol Reprod Biol 96:196–201.CrossRefGoogle Scholar
Enskog, A, Nilsson, L & Bränström, M (2001b). Low peripheral blood levels of the immunosuppressive cytokine interleukin-10 (IL-10) at the start of gonadotrophin stimulation indicates increased risk for development of ovarian hyperstimulation syndrome (OHSS). J Reprod Immunol 49:71–85.CrossRefGoogle Scholar
Evbuomwan, IO, Davison, JM & Murdoch, AP (2000). Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: volume homeostasis paradox. Fertil Steril 74:67–72.CrossRefGoogle ScholarPubMed
Evbuomwan, IO, Davison, JM, Baylis, PM et al. (2001). Altered osmotic thresholds for arginine vasopressin secretion and thirst during superovulation and in the ovarian hyperstimulation syndrome (OHSS): relevance to the pathophysiology of OHSS. Fertil Steril 75:933–41.CrossRefGoogle ScholarPubMed
Fernandez, , Tarlatzis, BC, Rzasa, QJ et al. (1985a). Renin like activity in ovarian follicular fluid. Fertil Steril 44:219–23.CrossRefGoogle Scholar
Fernandez, , Twickler, J & Mead, A (1985b). Neovascularization produced by angiotensin II. J Lab Clin Med 105:141–2.Google Scholar
Ferrara, N & Henzel, WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851–8.CrossRefGoogle ScholarPubMed
Ferrara, N, Houck, K, Jakeman, L et al. (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32.CrossRefGoogle ScholarPubMed
Frederick, JL, Shimanuki, T & DiZerega, GS (1984). Initiation of angiogenesis by human follicular fluid. Science 224:389–92.CrossRefGoogle ScholarPubMed
Friedlander, MA, Mola, JR & Goldfarb, JM (1993). Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril 60:826–32.CrossRefGoogle ScholarPubMed
Friedman, CI, Seifer, DB, Kennard, EA et al. (1998). Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertil Steril 64:268–72.Google Scholar
Geva, E, Amit, A, Lessing, JB et al. (1999). Follicular fluid levels of vascular endothelial growth factor. Are the premarkers for ovarian hyperstimulation syndrome?J Reprod Med 44:91–6.Google Scholar
Gitay-Goren, H, Soker, S, Vlodavsky, I et al. (1992). The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267:6093–8.Google ScholarPubMed
Glorioso, N, Atlas, SA, Laragh, JH et al. (1986). Prorenin in high concentrations in human ovarian follicular fluid. Science 233:1422–4.CrossRefGoogle ScholarPubMed
Goad, DL, Rubin, J, Wang, H et al. (1996). Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262–8.CrossRefGoogle ScholarPubMed
Goldsman, MP, Pedram, A, Dominguez, CE et al. (1995). Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 63:268–72.CrossRefGoogle ScholarPubMed
Gomez, R, Simon, C, Remohi, J et al. (2002). Vascular endothelial growth factor receptor-2 activation induces vascular permability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143:4338–49.CrossRefGoogle Scholar
Gomez, R, Simon, C, Remohi, J et al. (2003). Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 299:2164–71.CrossRefGoogle Scholar
Gomez, R, Lima, I, Simon, C & Pellicer, A (2004). Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats. Reproduction 127:483–9.CrossRefGoogle ScholarPubMed
Gordon, JD, Mesiano, S, Zaloudek, CJ et al. (1996). Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 81:353–9.Google ScholarPubMed
Gospodarowicz, D, Abraham, JA & Schilling, J (1989). Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci 86:7311–5.CrossRefGoogle ScholarPubMed
Handin RI & Wagner KK (1989). Molecular and cellular biology of von Willebrand factor. In (Coller, BS, Ed.), Progress in Hemostasis and Thrombosis. Philadelphia: WB Saunders, Vol. 9, p. 233.Google Scholar
Haning, RV, Estil, Y & Nolten, WE (1985). Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 66:220–4.Google ScholarPubMed
Hsueh, WA, Carlson, EJ & Dzau, VJ (1983). Characterization of inactive renin from human kidney and plasma: evidence of a renal source of circulating inactive renin. J Clin Invest 71:506–9.CrossRefGoogle ScholarPubMed
Itskovitz, J & Sealey, JE (1987). Ovarian prorenin-renin-angiotensin system. Obstet Gynecol Surv 42:545–9.CrossRefGoogle ScholarPubMed
Itskovitz, J, Bruneval, P, Soubrier, F et al. (1992). Localization of renin gene expression in monkey ovarian theca cells by in situ hybridization. J Clin Endocrinol Metab 75:1374–80.Google ScholarPubMed
Kaiser, UB (2003). The pathogenesis of the ovarian hyperstimulation syndrome. New Engl J Med 349:729–32.CrossRefGoogle ScholarPubMed
Kamat, BR, Brown, LF, Manseau, EJ et al. (1995). Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Am J Pathol 146:157–65.Google ScholarPubMed
Katz, Z, Lancet, M, Borenstein, R et al. (1984). Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 29:186–8.Google ScholarPubMed
Keck, PJ, Hauser, SD, Krivi, G et al. (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309–12.CrossRefGoogle ScholarPubMed
Kendall, RL & Thomas, KA (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705–9.CrossRefGoogle ScholarPubMed
Kim, KJ, Li, B, Winer, J et al. (1993). Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 362:841–4.CrossRefGoogle Scholar
Kishimoto, T (1989). The biology of IL-6. Blood 74:1–10.Google Scholar
Kitajima, Y, Endo, T, Manase, K et al. (2004). Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril 81(Suppl 2):842–9.CrossRefGoogle Scholar
Koch, AE, Harlow, , Haines, GK et al. (1994). Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152: 4149–56.Google ScholarPubMed
Krasnow, JJ, Berga, SL, Guzick, DS et al. (1996). Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome. Fertil Steril 65:552–5.CrossRefGoogle ScholarPubMed
Kwekkeboom, DJ, Jong, FH & Lamberts, SW (1989). Gonadotrophin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in-vitro: relation to sex and effects of thryotropin-releasing hormone, gonadotrophin-releasing hormone, and bromocriptine. J Clin Endocrinol Metab 68:1128–35.CrossRefGoogle Scholar
Lee, A, Christenson, LK, Stouffer, RL et al. (1997). Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in-vitro fertilization. Fertil Steril 68:305–11.CrossRefGoogle ScholarPubMed
Leung, DW, Cachianes, G, Kuang, WJ et al. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–9.CrossRefGoogle ScholarPubMed
Levin, I, Gamzu, R, Hasson, Y et al. (2004). Increased erythrocyte aggregation in ovarian hyperstimulation syndrome: a possible contributing factor in the pathophysiology of this disease. Hum Reprod 19:1076–80.CrossRefGoogle ScholarPubMed
Levy, T, Oriveto, R, Homburg, R et al. (1996). Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Hum Reprod 11:1177–9.CrossRefGoogle Scholar
Li, J, Perrella, MA, Tsai, JC et al. (1995). Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aotic smooth muscle cells. J Biol Chem 270:308–12.CrossRefGoogle Scholar
Lightman, A, Tarlatzis, BC, Rzasa, PJ et al. (1987). The ovarian renin–angiotensin system: renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated human follicular fluid. Am J Obstet Gynecol 156:808–16.CrossRefGoogle ScholarPubMed
Loret de Mola, JR, Flores, JP, Baumgardner, GP et al. (1996a). Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: ovarian imunohistochemical localization of interleukin-6 signal. Obstet Gynecol 87:581–7.Google Scholar
Loret de Mola, JR, Baumgardner, GP, Goldfarb, JM et al. (1996b). Ovarian hyperstimulation syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumor necrosis factor cannot predict its occurrence. Hum Reprod 11:1377–80.CrossRefGoogle Scholar
Ludwig, M, Gembruch, U, Bauer, O et al. (1998). Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with a fetal and placental triploidy: information about the general pathophysiology of OHSS. Hum Reprod 13:2082–7.CrossRefGoogle Scholar
Ludwig, M, Jekmann, W, Bauen, O et al. (1999). Prediction of severe ovarian hyperstimulation by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotropin administration. Hum Reprod 14:2437–41.CrossRefGoogle Scholar
Maathuis, JB, Look, PF & Michie, EA (1978). Changes in volume, total protein and ovarian steroid concentrations of peritoneal fluid through the human menstrual cycle. J Endocrinol 76:123–4.CrossRefGoogle ScholarPubMed
Mannucci, PM, Canciani, MT, Rota, L et al. (1981). Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Hematal 47:283–93.CrossRefGoogle ScholarPubMed
Manolopoulos, K, Lang, U, Gips, H et al. (2001). Elevated interleukin-10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 99:226–31.CrossRefGoogle ScholarPubMed
Mantovani, A, Bussolino, F & Introna, M (1997). Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 18:231–40.CrossRefGoogle Scholar
Mathur, RS, Jenkins, JM & Bansal, AS (1997). The probable role of the immune system in the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 12:2629–34.CrossRefGoogle Scholar
McClure, N, Healy, DL, Rogers, PA et al. (1994). Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344:235–6.CrossRefGoogle ScholarPubMed
McElhinney, B, Ardill, J, Caldwell, C et al. (2002). Variations in serum vascular endothelial growth factor binding profiles and the development of ovarian hyperstimulation syndrome. Fertil Steril 78:286–90.CrossRefGoogle ScholarPubMed
McLaren, J, Prentice, A, Charnock-Jones, DS et al. (1996). Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 11:220–3.CrossRefGoogle ScholarPubMed
Meyer, D, Pietu, G, Fressinaud, E et al. (1991). Von Willebrand factor: structure and function. Proc Mayo Clin 66:516–23.CrossRefGoogle ScholarPubMed
Millauer, B, Wizigmann-Voos, S, Schnurch, H et al. (1993). High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesisCell 72:835–46.CrossRefGoogle ScholarPubMed
Morris, RS, Wong, IL, Kirkham, E et al. (1995). Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 10:1355–8.CrossRefGoogle ScholarPubMed
Motro, B, Itin, A, Sacjs, L et al. (1990). Pattern of IL-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. J Cell Biol 87:3092–6.Google ScholarPubMed
Navot, D, Margalioth, E & Laufer, N (1987). Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48:57–61.CrossRefGoogle ScholarPubMed
Neufeld, G, Cohen, T, Gengrinovitch, S et al. (1999). Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal 13:9–22.CrossRefGoogle ScholarPubMed
Neulen, J, Yan, Z, Raczek, S et al. (1995a). Ovarian hyperstimulation syndrome: vascular endothelial growth factor/vascular permeability factor from luteinized granulosa cells is the patho-physiological principle. In Abstracts of the 11th Annual Meeting of the ESHRE, Hamburg.Google Scholar
Neulen, J, Yan, Z, Raczek, S et al. (1995b). Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80:1967–71.Google Scholar
Novella-Maestre, E, Gomez-Gallego, R, Alonso-Muriel, I et al. (2005). Progesterone has no role in the increased vascular permeability which onsets OHSS. J Soc Gyn Invest 12 (Suppl 364):202A.Google Scholar
Ogawa, S, Minakami, H, Araki, S et al. (2001). A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. J Assist Reprod Genet 18:114–19.CrossRefGoogle ScholarPubMed
Ohba, T, Ujioka, T, Ishikawa, K et al. (2003). Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication. Mol Cell Endocrinol 202:47–52.CrossRefGoogle ScholarPubMed
Ong, ACM, Eisen, V, Rennie, DP et al. (1991). The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endocrinol 34:43–9.CrossRefGoogle ScholarPubMed
Oppenheim JJ, Ruscetti FW & Faltynek C (1991). Cytokines. In (Stites, DP, Terr, AI, Eds), Basic and Clinical Immunology (7th Edn). East Norwalk, CT: Appleton and Lange, p. 78.Google Scholar
Orvieto, R, Voliovitch, I, Fishman, P et al. (1995). Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. Hum Reprod 10:24–7.CrossRefGoogle ScholarPubMed
Paulson, RJ, Do, YS, Hsueh, WA et al. (1989). Ovarian renin production in vitro and in vivo: characterization and clinical correlation. Fertil Steril 51:634–8.CrossRefGoogle ScholarPubMed
Peach, MJ (1977). Renin-angiotensin system: biochemistry and mechanism of action. Physiol Rev 57:313–7.CrossRefGoogle Scholar
Pellicer, A, Palumbo, A, DeCherney, AH et al. (1988). Blockage of ovulation by an angiotensin antagonist. Science 240:1660–1.CrossRefGoogle ScholarPubMed
Pellicer, A, Miru, F, Sampaia, M et al. (1991). In-vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17, 20 desmolase deficiency. Fertil Steril 55:970–5.CrossRefGoogle Scholar
Pellicer, A, Albert, C, Mercader, A et al. (1999). The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71:482–9.CrossRefGoogle ScholarPubMed
Penz-Vidovic, I, Skori, T, Grubisi, G et al. (2000). Evolution of clinical symptoms in a young woman with a recurrent gonadotroph adenoma causing ovarian hyperstimulation. Eur J Endocrinol 143:607–14.CrossRefGoogle Scholar
Pepperell JR, Nemeth G, Plaumbo A et al. (1993). The intraovarian renin–angiotensin system. In (Adashi, EY, Leung, PCK, Eds), The Ovary. New York: Raven Press, pp. 363–80.Google Scholar
Phillips, HS, Hains, J, Leung, DW et al. (1990). Vascular endothelial cell growth factor is expressed in rat corpus luteum. Endocrinology 127:965–7.CrossRefGoogle ScholarPubMed
Polishuk, WZ & Schenker, JG (1969). Ovarian overstimulation syndrome. Fertil Steril 20:443–5.CrossRefGoogle ScholarPubMed
Pride, SM, Ho Yuen, B, Moon, YS et al. (1986). Relationship of gonadotrophin-releasing hormone, danazol and prostaglandin blockage to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 154:1155–60.CrossRefGoogle Scholar
Pride, SM, James, C & Ho Yuen, B (1990). The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol 8:247–60.CrossRefGoogle Scholar
Ravindranath, N, Little-Ihrig, LL, Phillios, HS et al. (1992). Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinol 131: 254–60.CrossRefGoogle ScholarPubMed
Revel, A, Barak, V, Lavy, Y et al. (1996). Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 66:66–71.CrossRefGoogle ScholarPubMed
Rizk B (1992). Ovarian hyperstimulation syndrome. In (Brinsden, PR, Rainsbury, PA, Eds), A Textbook of In-Vitro Fertilization and Assisted Reproduction. Carnforth, UK: Parthenon Publishing, Chapter 23, pp. 369–83.Google Scholar
Rizk B (1993a). Ovarian hyperstimulation syndrome. In (Studd, J, Ed.), Progress in Obstetrics and Gynecology, Volume 11. Edinburgh: Churchill Livingstone, Chapter 18, pp. 311–49.Google Scholar
Rizk, B (1993b). Prevention of ovarian hyperstimulation syndrome: the Ten Commandments. European Society of Human Reproduction and Embryology Symposium, Tel Aviv, Israel, pp. 1–2.Google Scholar
Rizk B (2001). Ovarian hyperstimulation syndrome: prediction, prevention and management. In (Rizk, B, Devroey, P, Meldrum, DR, Eds), Advances and Controversies in Ovulation Induction. Proceedings of the 34th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 57th Annual Meeting, Orlando, FL, October 2001, pp. 23–46.Google Scholar
Rizk B (2002). Can OHSS in ART be eliminated? In (Rizk, B, Meldrum, D, Schoolcraft, W, Eds), A Clinical Step-By-Step Course For Assisted Reproductive Technologies. Proceedings of the 35th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 58th Annual Meeting, Seattle, WA, October 2002, pp. 65–102.Google Scholar
Rizk B & Abdalla H (2003). Pathogenesis of endometriosis. In (Rizk, B, Abdalla, H, Eds), Endometriosis, 2nd edn. Oxford: Health Press, Chapter 1, pp. 9–23.Google Scholar
Rizk, B & Aboulghar, M (1991). Modern management of ovarian hyperstimulation syndrome. Hum Reprod 6:1082–7.CrossRefGoogle ScholarPubMed
Rizk B & Aboulghar MA (1999). Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In (Brinsden, P, Ed.), A Textbook of In-Vitro Fertilization and Assisted Reproduction, 2nd edn. London: Parthenon Publishing, Chapter 9, pp. 131–55.Google Scholar
Rizk B & Aboulghar MA (2005). Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In (Brinsden, P, Ed.), A Textbook of In-Vitro Fertilization and Assisted Reproduction, 3rd edn. London: Parthenon Publishing, Chapter 12, pp. 217–58.CrossRefGoogle Scholar
Rizk B & Nawar MG (2004). Ovarian hyperstimulation syndrome. In (Serhal, P, Overton, C, Eds), Good Clinical Practice in Assisted Reproduction. Cambridge: Cambridge University Press, Chapter 8, pp. 146–66.CrossRefGoogle Scholar
Rizk B & Abdalla H (2006). Ovulatory dysfunction and its management. In (Rizk, B & Abdullah, M, Eds), Infertility and Assisted Reproductive Technology. Oxford: Health Press, Chapter 1, pp. 87–9.Google Scholar
Rizk, B & Smitz, J (1992). Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 7:320–7.CrossRefGoogle ScholarPubMed
Rizk, B, Meagher, S & Fisher, AM (1990). Ovarian hyperstimulation syndrome and cerebrovascular accidents. Hum Reprod 5:697–8.CrossRefGoogle ScholarPubMed
Rizk, B, Aboulghar, MA, Mansour, RT et al. (1991). Severe ovarian hyperstimulation syndrome: analytical study of twenty-one cases. Proceedings of the VII World Congress on In-Vitro Fertilization and Assisted Procreations, Paris. Hum Reprod 8:368–9.Google Scholar
Rizk, B, Aboulghar, MA, Smitz, J & Ron-El, R (1997). The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3:255–66.CrossRefGoogle ScholarPubMed
Roberts, JE, Spandorfer, S, Fasouliotis, SJ et al. (2005). Spontaneous ovarian hyperstimulation caused by a follicle-stimulating hormone-secreting pituitary adenoma. Fertil Steril 83:208–10.CrossRefGoogle ScholarPubMed
Rosenberg, ME, Mckinzie, JK, Mckenzie, LM et al. (1994). Increased ascitic fluid prorenin in the ovarian hyperstimulation syndrome. Am J Kidney Dis 23:427–9.CrossRefGoogle ScholarPubMed
Sahin, Y, Kontas, O, Muderris, II et al. (1997). Effects of angiotensin converting enzyme inhibitor cilasaprin and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Gynecol Endocrinol 11:231–6.CrossRefGoogle ScholarPubMed
Schenker, JG (1999). Clinical aspects of ovarian hyperstimulation syndrome. Eur J Gynecol Reprod Biol 85:10–3.CrossRefGoogle ScholarPubMed
Schenker, JG & Polishuk, WZ (1976). The role of prostaglandins in ovarian hyperstimulation syndrome. Obstet Gynecol Surv 31:74–8.CrossRefGoogle Scholar
Schenker, JG & Weinstein, D (1978). Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30:255–68.Google ScholarPubMed
Senger, DR, Galli, SJ, Dvorak, AM et al. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–5.CrossRefGoogle ScholarPubMed
Shimon, J, Rubinek, T, Bar-Hava, I et al. (2001). Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 86:3635–40.CrossRefGoogle ScholarPubMed
Shweiki, D, Itin, A, Neufeld, G et al. (1993). Patterns of expression on vascular endothelial growth factor (VEGF) receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 91:2235–43.CrossRefGoogle ScholarPubMed
Smitz, J, Camus, M, Devroey, P et al. (1990). Incidence of severe ovarian hyperstimulation syndrome after GnRH-agonist–HMG treatment in super ovulation in vitro fertilization. Hum Repord 5:933–7.CrossRefGoogle Scholar
Snyder, PJ (1985). Gonadotroph cell adenomas of the pituitary. Endocrinol Rev 6:552–63.CrossRefGoogle ScholarPubMed
Snyder, PJ (1987). Gonadotroph cell pituitary adenomas. Endocrinol Metab Clin North Am 16:755–64.Google ScholarPubMed
Soker, S, Takashima, S, Miao, H et al. (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoforms specific receptor for vascular endothelial growth factor. Growth Factors 92:735–45.Google Scholar
Tischer, E et al. (1989). Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 165:1198–206.CrossRefGoogle ScholarPubMed
Tollan, A, Holst, N, Forsdahl, F et al. (1990). Transcapillary fluid dynamics during ovarian stimulation for in-vitro fertilization. Am J Obstet Gynecol 162:554–6.CrossRefGoogle ScholarPubMed
Teruel, MJ, Carbonell, LF, Llanos, MC et al. (2002). Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 77:1256–60.CrossRefGoogle ScholarPubMed
Teruel, MJ, Carbonell, LF, Teruel, MG et al. (2001). Effect of angiotensin-converting enzyme inhibitor on renal function in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 76:1232–7.CrossRefGoogle ScholarPubMed
Todorow, S, Schricker, ST, Siebzinruebl, ER et al. (1993). Von Willebrand factor: an endothelial marker to monitor in vitro fertilization patients with ovarian hyperstimulation syndrome. Hum Reprod 8:2039–49.CrossRefGoogle ScholarPubMed
Valimaki, MJ, Tiitinen, A, Alfthan, H et al. (1999). Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in a 28 year old woman. J Clin Endocrinol Metab 84:4204–8.CrossRefGoogle Scholar
Beaumont, W (1872). Evaluation of hemoconcentration from hematocrit measurements. J Appl Physiol 5:712–3.Google Scholar
Meeren, A, Squiban, C, Guormelon, P et al. (1991). Differential regulation by IL-4 and IL-10 of radiation induced IL-6 and IL-8 production and ICAM-1 expression by human endothelial cells. Cytokine 11:831–8.CrossRefGoogle Scholar
Wang, LJ & Norman, RJ (1992). Concentrations of immunoreactive interleukin-1 and interleukin-2 in human preovulatory follicular fluid. Hum Reprod 7:147–50.CrossRefGoogle ScholarPubMed
Wang, LJ, Robertson, S, Seamark, RF et al. (1991). Lymphokines, including interleukin-2 alter gonadotrophin-stimulated progesterone production and proliferationof human granulosa-luteal cells in vitro. J Clin Endocrinol Metab 72:824–31.CrossRefGoogle Scholar
Wang, LJ, Pascoe, V, Petrucco, OM et al. (1992). Distribution of leukocyte subpopulations in the human corpus luteum. Hum Reprod 7:197–202.CrossRefGoogle ScholarPubMed
Wang, TH, Horng, SG, Chang, CL et al. (2002). Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87:3300–8.CrossRefGoogle ScholarPubMed
Yan, Z, Weich, HA, Bernart, W et al. (1993). Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in-vitro. J Clin Endocrinol Metab 77:1723–5.Google ScholarPubMed
Yarali, H, Fleige-Zahradka, BG, Yuen, BH et al. (1993). The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril 59: 657–61.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×